However, the latter approach is only feasible for a receptor expressed on the cell surface, which is not the case for NPM–ALK or other ALK-associated fusions, therefore justifying our approach to use peptides designed to enter tumor cells. The gene discussed is NPM1; the disease is neoplasm.